Premium
Treatment with agalsidase beta during pregnancy in Fabry disease
Author(s) -
Politei Juan M.
Publication year - 2010
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/j.1447-0756.2009.01164.x
Subject(s) - fabry disease , enzyme replacement therapy , medicine , lysosomal storage disease , pregnancy , alpha galactosidase , disease , urology , endocrinology , genetics , biology
Fabry disease is an X‐linked lysosomal storage disease caused by a deficiency of α‐galactosidase A, which leads to excessive accumulation of glycosphingolipids in most tissues in the body, with life‐threatening clinical consequences in the kidney, heart, and cerebrovascular system. Enzyme replacement therapy using exogenously produced α‐galactosidase has been available for treatment of this multisystem progressive disease since 2001. Two different preparations of enzyme replacement therapy for Fabry disease are available outside of the USA: agalsidase alfa and agalsidase beta. Despite being X‐linked, Fabry disease affects many female patients, and this report presents a successful pregnancy of a female patient receiving agalsidase beta.